Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Hyperphosphatemia

• A Study to Evaluate Safety and Efficacy of AP-306 in Hyperphosphatemia Patients
• A Phase 2 Dose-finding Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis
• Efficacy and Safety of Cholestyramine in the Management of Hyperphosphatemia in Adult Hemodialysis Patients
• Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease
• Auryxia (Ferric Citrate) Therapy for In-Center and Home Dialysis Participants
• Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis
• Clinical Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis
• Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis
• Clinical Study of KHK7791 in Hyperphosphatemia Patients on Peritoneal Dialysis
• A Phase 2 Study to Evaluate the Safety and Efficacy of VS-505 to Treat Hyperphosphatemia in Hemodialysis Patients
• Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia
• Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease
• Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis
• To Evaluate the Patient Tolerance, Pharmacodynamics and Pharmacokinetics of Lanthanum Polystyrene Sulfonate Powder
• Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients
• A Long-Term Study to Evaluate the Ability of Tenapanor Alone or in Combination With Sevelamer to Treat to Goal Serum Phosphorus in Patients With End-Stage Kidney Disease on Dialysis
• Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis
• Dose-finding Study of KHK7791 in Hyperphosphatemia Patients
• Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients
• Individualized Treatment of Hyperphosphatemia in Maintenance Hemodialysis Patients
• A Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on HD
• Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy
• PA21 Safety and Efficacy in Adult Chinese Subjects
• Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)
• A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis
• DS2330b Alone and With Sevelamer in Patients on Chronic Hemodialysis
• Assess the Safety and Efficacy of Nephoxil® in Subjects With End Stage Renal Disease (ESRD) on Dialysis
• Hyperphosphatemia in Children With Chronic Kidney Disease
• The Efficacy of Niacin on Hyperphosphatemia in Patients Undergoing Haemodialysis
• Transition to Ferric Citrate Among Hemodialysis and Peritoneal Dialysis Patients
• Evaluation of Renvela in Patients With Chronic Kidney Disease Not On Dialysis And Hyperphosphatemia In China
• A Phase1 Study to Explore the Safety of EOS789 in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis
• Nicotinic Acid in Hemodialysis Patients With Hyperphosphatemia
• Dose Range-finding Study of ASP1585 in Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia
• A Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent Chronic Kidney Disease (CKD) Patients With Hyperphosphataemia
• Non-interventional Study to Investigate the Short and Long Term Real-life Safety, Effectiveness, and Adherence of Velphoro® in Patients With Hyperphosphataemia Undergoing Haemodialysis (HD) or Peritoneal Dialysis (PD)
• An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)
• A Study of Ferric Citrate to Improve Inflammation and Lipid Levels
• Single and Multiple Dosing Study in Hemodialysis Patients With Hyperphosphatemia in Japan
• Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D
• Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia
• Study to Evaluate the Efficacy and Safety of PT20 in Subjects With Hyperphosphataemia and Dialysis Dependent Chronic Kidney Disease
• Dose Finding Study to Treat High Phosphate Levels in the Blood.
• Therapeutic Equivalence of OsvaRen® Tablets and OsvaRen® Granules
• Drug-Drug Interaction Study to Evaluate the Effect of Colestilan on the Pharmacokinetics of Single Doses of Candesartan Cilexetil in Healthy Subjects
• Fosrenol Post-marketing Surveillance in Japan
• Post-Marketing Surveillance on Long-Term Drug Use of Kiklin (Bixalomer)® Capsules in Patients With Hyperphosphatemia Receiving Peritoneal Dialysis
• Post-marketing Surveillance of Kiklin Capsules in Hemodialysis Patients
• Post Authorisation Safety Study of Renvela® in Chronic Kidney Disease Patients Not on Dialysis With Hyperphosphataemia
• The Effect of Magnesium Oxide on Plasma Phosphate in Hemodialysis Patients
• A Phase III Study of PA21 in Peritoneal Dialysis Patients With Hyperphosphatemia
• A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia
• A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia
• A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia
• Safety and Tolerability Study of MCI-196
• Long-term Extension Study of MCI-196
• Dose-finding Study of MCI-196
• Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients
• Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis
• A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis
• Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol
• A Study to Assess the Pharmacokinetics of Lanthanum Carbonate, Investigate and Compare the Efficacy, Safety and Tolerability of Lanthanum Carbonate With Calcium Carbonate in Hyperphosphataemic Children and Adolescents With Chronic Kidney Disease on
• Outcome Study of Lanthanum Carbonate Compared With Calcium Carbonate in Hemodialysis Patients : Landmark Study
• An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Participants With Chronic Kidney Disease
• A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on Dialysis
• PA21 Phase II Clinical Study in Hemodialysis Patients With Hyperphosphatemia
• Open Study of BAY77-1931 (Lanthanum Carbonate) in Continuous Ambulatory Peritoneal Dialysis Patients
• Phase III Double-blind Comparative Study of BAY77-1931 (Lanthanum Carbonate) With Calcium Carbonate
• A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Effects of Ferric Citrate in Subjects With End Stage Renal Disease
• Fosrenol Post-marketing Surveillance for Hemodialysis in Japan
• Fosrenol Post-marketing Surveillance for Continuous Cyclic Peritoneal Dialysis in Japan
• The Effect(s) of Sevelamer Carbonate (Renvela) on Atherosclerotic Plaque Inflammation Judged by FDG-PET Scan
• Nicotinamide in Hemodialysis Patients With Hyperphosphatemia
• A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis
• Long-term Study in Chronic Kidney Disease (Extension From Study 14817)
• Study in Chronic Kidney Disease (CKD) Not on Dialysis
• A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease
• Placebo Versus SBR759 in Lowering Phosphate in Dialysis Patients
• A Comparative Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis
• Hypophosphatemic Rickets in Norway
• Bioequivalence Study of BAY77-1931 Granule
• A Phase 3 Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Peritoneal Dialysis
• Trial of a New Formulation of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease
• Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis
• Phase III Study to Investigate the Safety and Efficacy of Fermagate and Sevelamer Hydrochloride
• Phase III Study to Investigate the Safety and Efficacy of Fermagate and Lanthanum Carbonate
• Effect of Sevelamer on Glucose Tolerance and Insulin Sensitivity in Patients With Chronic Renal Failure (CKD)
• A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphataemic Chronic Kidney Disease Patients Not on Dialysis
• Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia
• BAY 77-1931 Long-term Extension From Phase II Study
• Long-term Treatment on BAY77-1931 (Lanthanum Carbonate) to Measure Lanthanum Concentrations in Bone
• Bioequivalence Study Comparing Calcium Acetate Oral Solution Versus Calcium Acetate Gelcaps in Healthy Volunteers
• Efficacy of SBR759 in Lowering Serum Phosphate Levels in Chronic Kidney Disease Patients on Hemodialysis
• An Open Label Dose Titration of Sevelamer Carbonate Tabs 3 Times a Day in Hyperphosphatemic CKD Patients Not On Dialysis
• Chewed vs. Crushed Lanthanum Carbonate in Hemodialysis Patients
• A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)
• Long-term Effect of Lanthanum Carbonate on Bone
• A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia
• A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia
• Study to Assess Fixed Dosing of AMG 223 in Subjects With Chronic Kidney Disease on Hemodialysis With Hyperphosphatemia
• The Effect of Oral Niacinamide on Plasma Phosphorus Levels in Peritoneal Dialysis Patients
• A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia
• A Phase 2 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis
• Efficacy of Phosphate Binding in Healthy Volunteers: Chewed Versus Crushed Lanthanum Carbonate
• A Phase III, Multi-Centre, Randomised, Placebo-Controlled Study in Combination With Ca-based P Binders in Patients With Hyperphosphatemia
• Dose Ranging Study of Magnesium Iron Hydroxycarbonate in Haemodialysis Subjects With Hyperphosphataemia
• A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia
• Arterial Stiffness and Calcifications in Haemodialysis Patients on Sevelamer or Calcium Acetate
• Efficacy and Tolerability of ILY101 in Dialysis Patients With Hyperphosphatemia
• Efficacy and Safety Study of Magnesium Iron Hydroxycarbonate for the Reduction of High Blood Phosphate in Hemodialysis Patients
• The Effect of Oral Niacinamide on Serum Phosphorus Levels in Hemodialysis Patients
• EPIC(Effect of PhosLo on Phosphorus Levels in Chronic Kidney Disease)